Asthma Myths #3 - The Risks of Overuse of Short-Acting Beta Agonists (SABAs): A Growing Concern in Asthma Management
Although asthma management has evolved significantly, the reliance on short-acting beta-agonists (SABAs) as quick-relief medications remains a staple in many treatment plans.
While SABAs, such as salbutamol, are used for bronchodilation during an asthma attack, overuse can pose serious health risks. It's crucial for both patients and healthcare professionals to work together, engaging in open communication and collaboration, to effectively manage this condition.
Understanding SABAs
We must all understand that SABAs are bronchodilator medications that work by relaxing the muscles of the airways. This allows for improved airflow and relief from symptoms such as wheezing and shortness of breath.
Guidelines suggest that utilising these medications more than twice a week may indicate inadequate asthma control. This underscores the importance of reassessing a management plan, a proactive step that can significantly improve outcomes and may save lives.
Let's all listen to this podcast and be empowered to speak to our healthcare provider about better lung health.